PAP
CLYM

Persistent Asset Partners’s Climb Bio CLYM Stock Holding History

Persistent Asset Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-72,325
Closed -$495K – 929
2026
Q1 		$495K Buy
72,325
+63,097
+684% +$364K 0.18% 108
2025
Q4 		$36.9K Sell
9,228
-18,993
-67% -$45.6K 0.02% 302
2025
Q3 		$56.7K Sell
28,221
-116,958
-81% -$217K 0.04% 175
2025
Q2 		$180K Sell
145,179
-581
-0.4% -$723 0.13% 118
2025
Q1 		$178K Hold
145,760
– – 0.15% 102
2024
Q4 		$277K Buy
+145,760
New +$527K 0.23% 83

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Persistent Asset Partners's CLYM Position: Q2 2026 in Review

Persistent Asset Partners sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 72,325 shares — an estimated $495K sold.

Persistent Asset Partners first reported a position in CLYM in Q4 2024 and held it in 6 quarters. The position peaked at $495K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Persistent Asset Partners reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 72,325 Climb Bio shares in Q2 2026, an estimated $495K.
  • Persistent Asset Partners first reported a position in Climb Bio in Q4 2024 and held it in 6 quarters.
  • Persistent Asset Partners's Climb Bio position peaked at $495K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.